{"id":"NCT02896855","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-13","primaryCompletion":"2018-06-27","completion":"2021-01-22","firstPosted":"2016-09-12","resultsPosted":"2019-07-10","lastUpdate":"2021-12-16"},"enrollment":243,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":["Perjeta"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin"]}],"arms":[{"label":"Arm A: Placebo + Trastuzumab + Docetaxel","type":"ACTIVE_COMPARATOR"},{"label":"Arm B: Pertuzumab + Trastuzumab + Docetaxel","type":"EXPERIMENTAL"}],"summary":"This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in participants with previously untreated HER2-positive metastatic breast cancer.","primaryOutcome":{"measure":"Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","timeFrame":"From date of randomization until date of PFS event (Median [range] time on study for Arm A vs. Arm B at Primary analysis: 57.14 [3.3-93.3] weeks vs. 59.64 [0.9-90.4] weeks; Final analysis: 145.29 [3.3-225.3] weeks vs. 174.79 [0.9-226.1] weeks)","effectByArm":[{"arm":"Arm A: Placebo + Trastuzumab + Docetaxel","deltaMin":12.4,"sd":null},{"arm":"Arm B: Pertuzumab + Trastuzumab + Docetaxel","deltaMin":14.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0418"},{"comp":"OG000 vs OG001","p":"0.0556"},{"comp":"OG000 vs OG001","p":"0.0008"},{"comp":"OG000 vs OG001","p":"0.0019"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":15,"countries":["China"]},"refs":{"pmids":["32564260"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":120},"commonTop":["Leukopenia","Neutropenia","Anaemia","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}